First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study

Oncologist

Volumn 17, Issue 3, 2012, Pages 339-345

  Sastre, Javier ^a,b   Grávalos, Cristina ^c   Rivera, Fernando ^d   Massuti, Bartomeu ^e   Valladares Ayerbes, Manuel ^f   Marcuello, Eugenio ^g   Manzano, José L ^h   Benavides, Manuel ⁱ   Hidalgo, Manuel ^j   Díaz Rubio, Eduardo ^a   Aranda, Enrique ^k  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f HOSPITAL JUAN CANALEJO   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^j Centro Intregral Oncologico Clara Campal   (Spain)

^k HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

more..

Author keywords

Aged patients; Capecitabine; Cetuximab; Colorectal neoplasms

Indexed keywords

ANTIHISTAMINIC AGENT; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN;

ACUTE HEART INFARCTION; AGED; ANOREXIA; ARTICLE; ASTHENIA; BLEPHARITIS; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; DEEP VEIN THROMBOSIS; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRY SKIN; EYE DISEASE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPOMAGNESEMIA; KERATITIS; LIVER METASTASIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; ONCOGENE K RAS; OVERALL SURVIVAL; PARONYCHIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TREATMENT OUTCOME;

EID: 84859412772     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0406     Document Type: Article

References (27)

1. Gatta G, Faivre J, Capocaccia R et al. The EUROCARE Working Group. Survival of colorectal cancer patients in Europe during period 1978-1989. Eur J Cancer 1998;34:2176-2183.
2. Fentiman IS. Are the elderly receiving appropriate treatment for cancer? Ann Oncol 1996;7:657-658.
3. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341: 2061-2067.
4. Feliu J, Gonzàlez Barón M, Espinosa E et al. Uracil and tegafur modulated with leucovorin: An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. Cancer 1997;79:1884-1889.
5. Feliu J, Mel JR, Camps C et al. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: An active and low toxicity regimen. Eur J Cancer 2002;38:1204-1211.
6. Abad A, Aranda E, Navarro M et al. Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer. Rev Oncologia 2000;2:154-158.
7. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190-1197.
8. Feliu J, Escudero P, Llosa F et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: An Oncopaz Cooperative Group study. J Clin Oncol 2005;23:3104-3111.
9. Goldstein NI, Prewett M, Zulys K et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-1318.
10. Sastre J, Aranda A, Gràvalos C et al. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol 2011; 77:78-84.
11. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
12. Balducci L, Extermann M. Management of cancer in the older person: A practical approach. The Oncologist 2000;5:224-237.
13. Sastre J, Marcuello E, Masutti B et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study. J Clin Oncol 2005;23:3545-3551.
14. Feliu J, Salud A, Escudero P et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006;94:969-975.
15. Mitry E, Douillard JY, Van Cutsem E et al. Predictive factors of survival in patients with advanced colorectal cancer: An individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004;15:1013-1017.
16. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-4091.
17. Sastre J, Aranda E, Massuti B et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hemotol 2009;70:134-144.
18. Jackson NA, Barrueco J, Soufi-Mahjoubi R et al. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: Findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer 2009;115:2617-2629.
19. Aparicio T, Navazesh A, Boutron I et al. Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Crit Rev Oncol Hematol 2009;71:249-257.
20. Van Cutsem E, Köhne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-2019.
21. Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 2011;22:1535-1546.
22. Souglakos J, Pallis A, Kakolyris S et al. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial. Oncology 2005;69:384-390.
23. Comella P, Natale D, Farris A et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: Final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005;104:282-289.
24. Maughan TS, Adams R, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-2114.
25. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 2007;370:135-142.
26. Seymour MT, Maughan TS, Lederman JA et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 2007;370:143-152.
27. Jonker DJ, O Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048.